30.10
-0.34 (-1.12%)
| Penutupan Terdahulu | 30.44 |
| Buka | 30.39 |
| Jumlah Dagangan | 357,718 |
| Purata Dagangan (3B) | 433,247 |
| Modal Pasaran | 970,731,008 |
| Harga / Pendapatan (P/E TTM) | 12.86 |
| Harga / Pendapatan (P/E Ke hadapan) | 4.76 |
| Harga / Jualan (P/S) | 2.30 |
| Harga / Buku (P/B) | 4.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Feb 2025 - 24 Feb 2025 |
| Margin Keuntungan | 14.78% |
| Margin Operasi (TTM) | 35.17% |
| EPS Cair (TTM) | 2.34 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 16.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -54.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 373.23% |
| Nisbah Semasa (MRQ) | 0.970 |
| Aliran Tunai Operasi (OCF TTM) | 193.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 324.09 M |
| Pulangan Atas Aset (ROA TTM) | 9.67% |
| Pulangan Atas Ekuiti (ROE TTM) | 42.89% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Collegium Pharmaceutical, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.50 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.64% |
| % Dimiliki oleh Institusi | 122.05% |
| Julat 52 Minggu | ||
| Median | 37.00 (22.92%) | |
| Jumlah | 1 Pegang | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 11 Oct 2024 | 37.00 (22.92%) | Pegang | 37.72 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2024 | Pengumuman | Collegium to Participate in Upcoming Investor Conferences |
| 07 Nov 2024 | Pengumuman | Collegium Reports Record Third Quarter 2024 Financial Results |
| 07 Nov 2024 | Pengumuman | Collegium Appoints Vikram Karnani as Chief Executive Officer |
| 24 Oct 2024 | Pengumuman | Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |